ClinicalTrials.gg
RecruitingNCT07475780Updated Oct 7, 2026

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma

An interventional study of Ultrasound-guided RFA in Recurrent Parathyroid Carcinoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Parathyroid Neoplasms with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Parathyroid Neoplasms · United States.

Planned enrollment
17th of 21
20 · median 75
Started
2026
with 1 other
No phase
7 of 29
1 open now
Registered
29th of 29
by date
Lead sponsor
4 of 29
M.D. Anderson Cancer Center

Among the 29 studies in Parathyroid Neoplasms with a site in United States, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 29th registered.

Parathyroid Neoplasms

63 studies on the registry are indexed under Parathyroid Neoplasms; 19 are open to participants now.

Browse Parathyroid Neoplasms studies →

Open to participants now

8 of the 29 studies in Parathyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Parathyroid Neoplasms studies recruiting now, 7 (70%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Parathyroid Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The study will be an effectiveness study. The study will include enrollment of a total of 20 patients with at least one PC lesion for ultrasound guided RFA to PC recurrence in the neck to assess the effectiveness in reducing patient's hypercalcemia. Patients will have surgically proven PC from prior parathyroidectomy and suspicious PC visible on ultrasound and request for treatment for uncontrolled hypercalcemia (Figure 1).

Read the detailed description

Primary Objective:

  • Evaluate treatment response of RFA of recurrent PC by means of longitudinal monitoring patient serum calcium level and PTH.

Secondary Objectives:

  • Evaluate the sonographic features of the recurrent PC induced by RFA.
  • Evaluation of procedure-related complications
  • Disease free survival until recurrence of hypercalcemia
03

Conditions studied

  • Recurrent Parathyroid Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients with recurrent parathyroid carcinoma that was previously resected and persistent or recurrent hypercalciemia. Patients are not surgical candidates or strongly desire nonsurgical intervention. Eligibility for enrollment will be based upon meeting inclusion and exclusion criteria as detailed in section 4.1 and 4.2.

The study will include 20 eligible patients or lesions. Utmost care will be taken to minimize risk to patients through careful selection of patients and scheduled assessments (Table 1). Patients will be recruited through the Endocrine, Endocrine surgery, Head and Neck Surgery Clinics, as well as Neuro-Interventional Radiology Ultrasound. All patients who meet the inclusion and exclusion criteria and agree to participate in the study will be consented and then enrolled into the study. No other criteria, apart from the eligibility criteria detailed below, will be used for subject selection. We anticipate enrolling approximately 1 patient every 2 months (0.5 patients/month), for a total accrual period of up to 40 months to reach the planned sample size of 20 patients. Each participant will be followed for 12 months after RFA, so the total study duration is estimated at approximately 52 months from first patient enrollment to last patient follow-up.

Candidates for this study must meet all of the following inclusion criteria:

  1. Patient is older than 18 years, is not a surgical candidate or refuses to have surgery.
  2. Patient is medically fit to undergo local anesthesia with or without conscious sedation.
  3. Patient is able to understand and give consent to participation in the study.
  4. Confirmed parathyroid carcinoma by prior surgery and histopathology.
  5. Presence of local recurrence or implant in the neck visible on ultrasound.
  6. Distant oligometastasis visible on ultrasound.
  7. Solid nodule without macrocalcification or internal cystic degeneration
  8. Patient who is off of Cinacalcet
  9. Entirety of the selected nodule is visible on ultrasound without significant extension posterior to trachea or mediastinal component (ie Type A, E, or high F).
  10. Selected nodule is amenable to medial or lateral approach.
  11. Normal complete blood count, blood coagulation.
  12. Patient agrees to participate in the clinical study and to complete all required visits and evaluations.
  13. Negative serum or urine pregnancy test for females of at baseline pre-procedure evaluation.

Exclusion criteria

Exclusion Criteria:

Candidates will be ineligible for enrollment in the study if any of the following conditions apply:

  1. Patients with cardiac arrhythmia and/or implanted cardiac device
  2. Surgically naïve parathyroid lesions, parathyroid adenoma or atypical parathyroid tumor.
  3. Pregnancy
  4. Allergies to medications for anesthesia.
  5. Cystic nodules (\< 70% solid components)
  6. Calcified nodules
  7. Targeted nodule within 0.5 cm from the major vessels, vagus nerve, brachial plexus, and recurrent laryngeal nerve.
  8. Patients with contralateral vocal cord paralysis.
  9. Uncorrectable coagulopathy with >1.5 X or INR >1.5 or count \<100,000 per mm3
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment with Ultrasound-guide RFA

    Participants treatment will be administered on an outpatient basis.

    Device: Ultrasound-guided RFA

Interventions

  • DeviceUltrasound-guided RFA

    Participants will be positioned supine with full neck extension. Preprocedural intraoperative PTH will be drawn. Radiofrequency ablation (RFA) will be performed on one or up to 5 nodules on ipsilateral side per participant.

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2031
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07475780
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Apr 9, 2026
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2031 (estimated)
Last update
Oct 7, 2026

Study contacts

Thinh Vu, MD
Contact
thinh.vu@mdanderson.org
(281) 415-2061
Thinh Vu, MD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion